2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.07B.03 Analysis of 30- And 90-day Mortality after Lung SBRT as an Indicator for Its Appropriateness

Pdf Summary

The study, conducted by Gregory M. M. Videtic at the Taussig Cancer Institute, evaluates the appropriateness of Stereotactic Body Radiation Therapy (SBRT) in treating medically inoperable lung cancer by analyzing 30-day and 90-day mortality rates. Lung SBRT is known for its excellent local control and minimal side effects, yet competing patient comorbidities at diagnosis can impact the decision-making process regarding its suitability.<br /><br />The study surveyed a 20-year dataset from 2003 to 2023, including 1,819 patients with early-stage lung cancer who opted for SBRT over surgical resection. It excluded those with oligometastases or treated for salvage. The analysis aimed to identify any factors potentially leading to early mortality post-treatment. Patient demographics showed a median age of 74.2 years, with a slight female majority (52.9%), and the median Karnofsky Performance Status (KPS) was 80.<br /><br />Within 90 days of SBRT, 3% of patients (54 individuals) died, with 8 deaths occurring within 30 days. None of these deaths were attributed to the SBRT treatment itself. Cardiovascular issues were the predominant cause of death, followed by pulmonary and cancer-related causes. Multivariate analysis identified male gender, low body-mass index, high Charlson comorbidity scores, and low KPS as risk factors for 90-day mortality.<br /><br />The conclusions emphasize that early deaths were infrequent and unrelated to SBRT, reaffirming its safety in treating lung cancer. However, cardiovascular comorbidities were significant contributors to early post-treatment mortality. Thus, while SBRT remains effective for cancer outcomes, a comprehensive assessment of cardiovascular risks should be considered when evaluating the treatment's appropriateness for individual patients.

Asset Subtitle

Gregory Videtic

Meta Tag

Speaker Gregory Videtic

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

Stereotactic Body Radiation Therapy

SBRT

lung cancer

30-day mortality

90-day mortality

comorbidities

cardiovascular risks

patient demographics

early-stage lung cancer

treatment safety